Plain-English translation of ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a medication called can help prevent acute kidney injury from developing into long-term kidney disease. Researchers believe this medication may work by reversing harmful changes in kidney cells that occur after heart surgery. The study will compare patients who receive the medication with those who receive a placebo (an inactive treatment) to see if it makes a difference.
Right now, doctors have no proven medications to treat acute kidney injury or prevent it from becoming chronic kidney disease. Most patients only receive supportive care and monitoring. This trial exists because early research suggests this medication might actually prevent the progression of kidney damage—which would be a major breakthrough.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the medication or a placebo, both given as injections under the skin. The trial will monitor your kidney function and overall health over time to see whether the medication helps prevent your kidney injury from becoming a long-term problem. You'll have blood tests and follow-up visits to track how your kidneys are recovering.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Taiwan